Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $148,500.00 in Stock

Key Points

• Adaptive Biotechnologies insider Harlan Robins sold 10,000 shares at an average price of $14.85 for a total of $148,500 on April 8 under a pre-arranged Rule 10b5-1 plan, leaving him with 1,512,058 shares (a 0.66% reduction).
• Shares fell 4.6% to $12.79 on heavy volume; the stock has a market cap of about $1.97 billion, a negative P/E (~-31.97) and a 12‑month range of $6.77–$20.76.
• Adaptive beat quarterly expectations with EPS of -$0.09 (vs. -$0.19 est.) and revenue of $71.68M (vs. $59.38M, +51% YoY), and analysts hold a consensus “Moderate Buy” rating with an average target of $18.25 (several firms raising targets to $21).

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Harlan Robins sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $14.85, for a total transaction of $148,500.00. Following the completion of the sale, the insider directly owned 1,512,058 shares of the company's stock, valued at approximately $22,454,061.30. This represents a 0.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Stock Down 4.6%

ADPT stock traded down $0.61 during trading on Friday, hitting $12.79. The company had a trading volume of 3,310,057 shares, compared to its average volume of 2,060,273. The firm has a 50-day moving average price of $15.07 and a 200-day moving average price of $15.96. Adaptive Biotechnologies Corporation has a 12 month low of $6.77 and a 12 month high of $20.76. The stock has a market cap of $1.97 billion, a price-to-earnings ratio of -31.97 and a beta of 2.29.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.10. The company had revenue of $71.68 million during the quarter, compared to analysts' expectations of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The business's revenue for the quarter was up 51.0% on a year-over-year basis. During the same period last year, the firm earned ($0.23) EPS. Equities analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Piper Sandler set a $21.00 target price on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. JPMorgan Chase & Co. boosted their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an "overweight" rating in a research note on Friday, February 6th. Guggenheim raised their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a "buy" rating in a research note on Monday, January 26th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Finally, TD Cowen reiterated a "buy" rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Adaptive Biotechnologies presently has a consensus rating of "Moderate Buy" and an average target price of $18.25.

Institutional Trading of Adaptive Biotechnologies

A number of hedge funds have recently modified their holdings of ADPT. AQR Capital Management LLC increased its stake in Adaptive Biotechnologies by 45.8% in the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company's stock valued at $2,265,000 after purchasing an additional 97,444 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Adaptive Biotechnologies by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company's stock worth $511,000 after purchasing an additional 2,914 shares in the last quarter. Caxton Associates LLP acquired a new position in shares of Adaptive Biotechnologies in the 1st quarter valued at $93,000. New York State Common Retirement Fund grew its holdings in shares of Adaptive Biotechnologies by 39.2% in the 2nd quarter. New York State Common Retirement Fund now owns 47,258 shares of the company's stock valued at $551,000 after buying an additional 13,300 shares during the period. Finally, Quantbot Technologies LP bought a new stake in shares of Adaptive Biotechnologies in the 2nd quarter valued at $587,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.